ERBB2 and gastric cancer: T-DXd efficacy has been consistently reported in HER2-positive metastatic gastric cancer both in the Asiatic (DESTINY-Gastric01 trial)88 and in the Western population (DESTINY-Gastric02 trial),94 with preliminary data of safety and tolerability with fluoropyrimidine combinations (DESTINY-Gastric03 trial).95 The results shown by T-DXd in BC, NSCLC, and gastric cancer promoted its investigation in other HER2-expressing tumors.